Valuation: Integrity Applications, Inc.

Market Cap 48.82L 42.44L 39.5L 36.27L 68.49L 47Cr 69.55L 4.66Cr 1.83Cr 23Cr 1.83Cr 1.79Cr 78Cr P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value 9L 8L 8L 7L 13.26L 9.02Cr 13.47L 90.15L 35.38L 4.49Cr 35.5L 34.72L 15Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
84.22%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 48.82L
-1.40%+2.59%-1.71%+11.28% 4.94TCr
-1.05%+13.07%+26.57%+5.13% 3.91TCr
-1.63%-0.14%+407.03%+619.89% 4.09TCr
-2.04%-3.39%+4.55%+46.97% 3.58TCr
-1.74%+8.42%+8.85%+48.87% 3.05TCr
-2.31%-3.44% - - 1.66TCr
-0.31%-4.40%+34.57%+127.08% 1.61TCr
+0.74%+0.42%-1.62%-33.79% 1.28TCr
-0.64%+2.65%+1.25%+8.92% 1.37TCr
Average +0.58%+5.78%+59.94%+104.29% 2.83TCr
Weighted average by Cap. -1.28%+6.72%+77.93%+130.08%

Financials

2024 2025
Net sales - -
Net income -2.26Cr -1.96Cr -1.83Cr -1.68Cr -3.17Cr -215.71Cr -3.22Cr -22Cr -8.46Cr -107.39Cr -8.49Cr -8.3Cr -360.1Cr -1.94Cr -1.69Cr -1.57Cr -1.44Cr -2.72Cr -185.08Cr -2.76Cr -18Cr -7.26Cr -92Cr -7.28Cr -7.12Cr -308.96Cr
Net Debt -53.5L -46.51L -43.29L -39.74L -75.05L -51Cr -76.22L -5.1Cr -2Cr -25Cr -2.01Cr -1.97Cr -85Cr -39.37L -34.22L -31.86L -29.25L -55.23L -38Cr -56.09L -3.75Cr -1.47Cr -19Cr -1.48Cr -1.45Cr -63Cr
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-